FASN is another key player implicated in poor prognosis and drug resistance in DLBCL, Zhong et al. [112] reported that FASN is markedly elevated in DLBCL patients with worse prognoses, particularly those adriamycin (ADM) chemotherapy. Here, FASN is linked to diffuse large B-cell lymphoma.